单位:[1]Huazhong Univ Sci & Technol,Tongji Med Coll,Dept Integrated Tradit Chinese & Western Med,Tongji Hosp,Wuhan,Peoples R China中医科中西医结合科华中科技大学同济医学院附属同济医院[2]Wuhan Univ, Zhongnan Hosp, Dept Nephrol, Wuhan, Peoples R China
The morbidity and mortality of autoimmune diseases (Ads) have been increasing worldwide, and the identification of novel therapeutic strategies for prevention and treatment is urgently needed. Sirtuin 1 (SIRT1), a member of the class III family of nicotinamide adenine dinucleotide (NAD(+))-dependent histone deacetylases, has been reported to participate in the progression of several diseases. SIRT1 also regulates inflammation, oxidative stress, mitochondrial function, immune responses, cellular differentiation, proliferation and metabolism, and its altered functions are likely involved in Ads. Several inhibitors and activators have been shown to affect the development of Ads. SIRT1 may represent a novel therapeutic target in these diseases, and small molecules or natural products that modulate the functions of SIRT1 are potential therapeutic agents. In the present review, we summarize current studies of the biological functions of SIRT1 and its role in the pathogenesis and treatment of Ads.
第一作者单位:[1]Huazhong Univ Sci & Technol,Tongji Med Coll,Dept Integrated Tradit Chinese & Western Med,Tongji Hosp,Wuhan,Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Shen Pan,Deng Xuan,Chen Zhe,et al.SIRT1: A Potential Therapeutic Target in Autoimmune Diseases[J].FRONTIERS IN IMMUNOLOGY.2021,12:doi:10.3389/fimmu.2021.779177.
APA:
Shen, Pan,Deng, Xuan,Chen, Zhe,Ba, Xin,Qin, Kai...&Tu, Shenghao.(2021).SIRT1: A Potential Therapeutic Target in Autoimmune Diseases.FRONTIERS IN IMMUNOLOGY,12,
MLA:
Shen, Pan,et al."SIRT1: A Potential Therapeutic Target in Autoimmune Diseases".FRONTIERS IN IMMUNOLOGY 12.(2021)